Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
LivaNova PLC stock logo
LIVN
LivaNova
$35.58
+1.5%
$40.33
$32.48
$64.48
$1.93B0.9626,871 shs614,570 shs
Envista Holdings Co. stock logo
NVST
Envista
$15.19
+1.1%
$17.93
$14.22
$23.00
$2.62B1.122.48 million shs2.10 million shs
RxSight, Inc. stock logo
RXST
RxSight
$14.43
-0.6%
$24.13
$13.50
$66.54
$584.29M1.26616,150 shs1.07 million shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$88.24
+3.3%
$72.08
$55.00
$177.37
$2.97B2.141.34 million shs971,082 shs
7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
LivaNova PLC stock logo
LIVN
LivaNova
+1.45%+4.22%-11.95%-26.34%-31.41%
Envista Holdings Co. stock logo
NVST
Envista
+1.05%-2.29%-10.11%-23.40%-22.49%
RxSight, Inc. stock logo
RXST
RxSight
-0.62%+1.69%-43.92%-52.52%-72.69%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
+3.35%+15.54%+27.90%+54.27%+0.43%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
LivaNova PLC stock logo
LIVN
LivaNova
3.5695 of 5 stars
4.43.00.00.02.91.71.3
Envista Holdings Co. stock logo
NVST
Envista
4.3837 of 5 stars
4.02.00.03.82.80.02.5
RxSight, Inc. stock logo
RXST
RxSight
3.0286 of 5 stars
4.11.00.00.03.82.50.6
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.8144 of 5 stars
3.42.00.00.02.31.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
LivaNova PLC stock logo
LIVN
LivaNova
2.88
Moderate Buy$61.1771.91% Upside
Envista Holdings Co. stock logo
NVST
Envista
2.07
Hold$19.9631.45% Upside
RxSight, Inc. stock logo
RXST
RxSight
2.20
Hold$37.60160.57% Upside
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.82
Moderate Buy$122.7039.05% Upside

Current Analyst Ratings Breakdown

Latest RXST, NVST, TMDX, and LIVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2025
Envista Holdings Co. stock logo
NVST
Envista
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$16.00
4/15/2025
RxSight, Inc. stock logo
RXST
RxSight
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$18.00
4/9/2025
RxSight, Inc. stock logo
RXST
RxSight
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$45.00 ➝ $16.00
4/4/2025
RxSight, Inc. stock logo
RXST
RxSight
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Underweight$40.00 ➝ $17.00
4/3/2025
RxSight, Inc. stock logo
RXST
RxSight
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$35.00 ➝ $22.00
4/3/2025
RxSight, Inc. stock logo
RXST
RxSight
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Underperform$36.00 ➝ $22.00
4/3/2025
RxSight, Inc. stock logo
RXST
RxSight
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$43.00 ➝ $43.00
3/26/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
3/21/2025
RxSight, Inc. stock logo
RXST
RxSight
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$60.00 ➝ $36.00
3/19/2025
RxSight, Inc. stock logo
RXST
RxSight
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$33.00 ➝ $28.00
3/17/2025
LivaNova PLC stock logo
LIVN
LivaNova
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$64.00 ➝ $64.00
(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
LivaNova PLC stock logo
LIVN
LivaNova
$1.25B1.54$3.19 per share11.15$23.72 per share1.50
Envista Holdings Co. stock logo
NVST
Envista
$2.51B1.04$1.18 per share12.91$17.04 per share0.89
RxSight, Inc. stock logo
RXST
RxSight
$139.93M4.18N/AN/A$4.47 per share3.23
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$441.54M6.73$0.17 per share530.08$4.20 per share21.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
LivaNova PLC stock logo
LIVN
LivaNova
$17.55M$1.1484.7111.33N/A1.91%13.81%7.07%4/29/2025 (Estimated)
Envista Holdings Co. stock logo
NVST
Envista
-$1.12B-$6.49N/A12.551.27-44.56%3.86%2.21%5/1/2025 (Estimated)
RxSight, Inc. stock logo
RXST
RxSight
-$48.61M-$0.72N/AN/AN/A-23.92%-14.00%-12.51%5/5/2025 (Estimated)
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$25.03M$1.0193.8761.71N/A8.14%18.74%4.39%4/29/2025 (Estimated)

Latest RXST, NVST, TMDX, and LIVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
LivaNova PLC stock logo
LIVN
LivaNova
$0.75N/AN/AN/A$302.34 millionN/A
5/5/2025N/A
RxSight, Inc. stock logo
RXST
RxSight
-$0.03N/AN/AN/A$38.74 millionN/A
5/1/2025Q1 2025
Envista Holdings Co. stock logo
NVST
Envista
$0.21N/AN/AN/A$608.17 millionN/A
4/29/2025Q1 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.29N/AN/AN/A$123.39 millionN/A
2/25/2025Q4 2024
RxSight, Inc. stock logo
RXST
RxSight
$0.10-$0.15-$0.25-$0.15$40.23 million$40.21 million
2/5/2025Q4 2024
Envista Holdings Co. stock logo
NVST
Envista
$0.23$0.24+$0.01$0.01$646.28 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
LivaNova PLC stock logo
LIVN
LivaNova
N/AN/AN/AN/AN/A
Envista Holdings Co. stock logo
NVST
Envista
N/AN/AN/AN/AN/A
RxSight, Inc. stock logo
RXST
RxSight
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
LivaNova PLC stock logo
LIVN
LivaNova
0.46
3.37
2.87
Envista Holdings Co. stock logo
NVST
Envista
0.44
2.04
1.76
RxSight, Inc. stock logo
RXST
RxSight
N/A
12.67
11.71
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.42
8.20
7.33

Institutional Ownership

CompanyInstitutional Ownership
LivaNova PLC stock logo
LIVN
LivaNova
97.64%
Envista Holdings Co. stock logo
NVST
Envista
N/A
RxSight, Inc. stock logo
RXST
RxSight
78.78%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%

Insider Ownership

CompanyInsider Ownership
LivaNova PLC stock logo
LIVN
LivaNova
0.27%
Envista Holdings Co. stock logo
NVST
Envista
1.30%
RxSight, Inc. stock logo
RXST
RxSight
9.36%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
7.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
LivaNova PLC stock logo
LIVN
LivaNova
2,90054.35 million54.15 millionOptionable
Envista Holdings Co. stock logo
NVST
Envista
12,700172.19 million169.95 millionOptionable
RxSight, Inc. stock logo
RXST
RxSight
22040.49 million36.53 millionOptionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
21033.66 million31.21 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LivaNova stock logo

LivaNova NASDAQ:LIVN

$35.58 +0.51 (+1.45%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$35.58 0.00 (-0.01%)
As of 04/17/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

Envista stock logo

Envista NYSE:NVST

$15.19 +0.17 (+1.12%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$15.16 -0.03 (-0.18%)
As of 04/17/2025 04:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

RxSight stock logo

RxSight NASDAQ:RXST

$14.43 -0.09 (-0.62%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$14.46 +0.04 (+0.24%)
As of 04/17/2025 05:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

TransMedics Group stock logo

TransMedics Group NASDAQ:TMDX

$88.24 +2.86 (+3.35%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$88.48 +0.24 (+0.27%)
As of 04/17/2025 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.